The Coronavirus Disease 2019 Pandemic is Associated with a Substantial Rise in Frequency and Severity of Presentation of Youth-Onset Type 2 Diabetes.
Journal Article (Multicenter Study;Journal Article)
OBJECTIVES: To evaluate the frequency and severity of new cases of youth-onset type 2 diabetes in the US during the first year of the pandemic compared with the mean of the previous 2 years. STUDY DESIGN: Multicenter (n = 24 centers), hospital-based, retrospective chart review. Youth aged ≤21 years with newly diagnosed type 2 diabetes between March 2018 and February 2021, body mass index ≥85th percentile, and negative pancreatic autoantibodies were included. Demographic and clinical data, including case numbers and frequency of metabolic decompensation, were compared between groups. RESULTS: A total of 3113 youth (mean [SD] 14.4 [2.4] years, 50.5% female, 40.4% Hispanic, 32.7% Black, 14.5% non-Hispanic White) were assessed. New cases of type 2 diabetes increased by 77.2% in the year during the pandemic (n = 1463) compared with the mean of the previous 2 years, 2019 (n = 886) and 2018 (n = 765). The likelihood of presenting with metabolic decompensation and severe diabetic ketoacidosis also increased significantly during the pandemic. CONCLUSIONS: The burden of newly diagnosed youth-onset type 2 diabetes increased significantly during the coronavirus disease 2019 pandemic, resulting in enormous strain on pediatric diabetes health care providers, patients, and families. Whether the increase was caused by coronavirus disease 2019 infection, or just associated with environmental changes and stressors during the pandemic is unclear. Further studies are needed to determine whether this rise is limited to the US and whether it will persist over time.
Full Text
- Published version (via Digital Object Identifier)
- Pubmed Central version
- Open Access Copy from Duke
- Link to Item
Duke Authors
Cited Authors
- Magge, SN; Wolf, RM; Pyle, L; Brown, EA; Benavides, VC; Bianco, ME; Chao, LC; Cymbaluk, A; Balikcioglu, PG; Halpin, K; Hsia, DS; Huerta-Saenz, L; Kim, JJ; Kumar, S; Levitt Katz, LE; Marks, BE; Neyman, A; O'Sullivan, KL; Pillai, SS; Shah, AS; Shoemaker, AH; Siddiqui, JAW; Srinivasan, S; Thomas, IH; Tryggestad, JB; Yousif, MF; Kelsey, MM; COVID-19 and Type 2 Diabetes Consortium,
Published Date
- December 2022
Published In
Volume / Issue
- 251 /
Start / End Page
- 51 - 59.e2
PubMed ID
- 35985535
Pubmed Central ID
- PMC9383958
Electronic International Standard Serial Number (EISSN)
- 1097-6833
Digital Object Identifier (DOI)
- 10.1016/j.jpeds.2022.08.010
Language
- eng
Conference Location
- United States